Imported drugs account for just 3 percent of the Iran’s pharmaceutical market
97% of the medicine in Iranian pharmaceutical market is produced locally and only 3% is being imported.
Based on reports released by Food and Drug Administration of Iran, 7,500 pharmaceutical products from the Iranian pharmaceutical market are domestically produced, and 2,500 items are imported drugs from abroad, which constitute only 3% of the country's market and hence most of the market needs are met by the local pharmaceutical companies.
Government of Iran, after the 1979 Islamic revolution, has devoted considerable resources on national health, including the pharmaceutical sector. As a result, health indicators have improved substantially over the past two decades, and the availability and affordability of medicines have also been greatly improved.
At the beginning of the revolution, there were 2,100 pharmaceutical products available in the country, of which 1,300 were imported drugs, 300 to 400 were licensed ones, and 550 ones were produced by domestic pharmaceutical manufacturers, but today, despite the imposed sanctions in this course of time, there are now 10,000 accessible pharma products in the market.
The United States has imposed an almost total economic embargo on Iran, which includes sanctions on companies doing business with Iran.
Currently, there are 110 pharmaceutical plants active in the country and about 30 pharmaceutical manufacturers committed to produce their products in these plants on a contract basis.